News

Precision BioSciences stock rises after FDA grants orphan drug status
Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...
Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight into ...
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
MyChesCo on MSN5h
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data
ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial ...
Investing Snacks9h
Vertex Pharmaceuticals Takes Charge in Cystic Fibrosis Market
Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...
Savara: Repairing The Molbreevi aPAP Opportunity After RTF
Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies
In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability ...
The Pharma Letter22h
ImCheck doubles up on orphan designations for ICT01 in AML
French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...